INTRODUCTION
F-box proteins (FBXs) are defined by the shared protein-protein interaction domain called F-box. Based on the existence of additional structural motifs, FBXs are divided into three subfamilies, including FBXW (for the WD40 domain), FBXL (for leucine-rich motif), and FBXO (for other motifs) (Jin et al., 2004) . FBXs often interact with a specific motif on the substrate called degron. Since the interactions between the best-characterized FBXs and their substrates are regulated by phosphorylation of the degron (Kõ ivomä gi et al., 2011; Liu et al., 2002; Nash et al., 2001; Wei et al., 2005) , the term phosphodegron was coined to epitomize regulation between FBXs and their substrates (Skaar et al., 2013) . However, it is increasingly clear that many FBX-substrate interactions are either based on recognition of the unmodified degron sequence (D'Angiolella et al., 2010 (D'Angiolella et al., , 2012 or recognition of degron with other covalent modification, such as glycosylation (Yoshida et al., 2002) . More recently, phosphorylation of degron has been shown to inhibit FBXL12 binding to p85b subunit of PI3K (Kuchay et al., 2013) .
The biological function of FBX is informed by their specific substrates. By conferring substrate specificity to the SCF ubiquitin E3 ligases, FBXs regulate a variety of cellular functions, including the cell cycle (Carrano et al., 1999; Frescas and Pagano, 2008) , signal transduction (Kõ ivomä gi et al., 2011; Kuchay et al., 2013; Liu et al., 2002; Nash et al., 2001; Wei et al., 2005) , DNA repair (D'Angiolella et al., 2012) , and genomic instability (Puklowski et al., 2011) , among others (Skaar et al., 2013) . Despite the extensive effort, the substrates for the majority of FBXs remain to be identified. This gap prevents us from fully understanding the function and mechanism of action of FBX. Identification of the substrates for the orphan FBX is a major focus in cell biology, as these efforts not only clarify the function of the orphan FBXs but also elucidate, to our knowledge, novel cellular regulatory pathways.
FBXO30 is an orphan FBX with no known substrates. Here, we take a reverse genetic approach to evaluate the function of Fbxo30 in mice. Our data revealed an unexpected function of the Fbxo30 gene in mammopoiesis, including branch morphogenesis and defective production of mature luminal epithelial cells. Mass spectrometry analysis of Fbxo30-associated proteins revealed motor protein Eg5 as Fbxo30 substrate. By regulating Eg5 abundance, Fbxo30 regulates mitosis and mammopoiesis. Our data not only revealed an unexpected function of Fbxo30 in organogenesis but also identified it as a critical regulator for mitosis.
With identification of mammary stem cells Stingl et al., 2006) , the mouse has emerged as a major tool to study mammopoiesis. Accumulating data led to a developmental pathway for differentiation of mammary stem cells into progenitors for basal myoepithelial and luminal epithelial cells, respectively Stingl et al., 2006; Visvader, 2009; Visvader and Stingl, 2014) . Genetic studies indicate critical roles for Slug and Sox9 as key determinants of mammary stem cell function (Guo et al., 2012) . Commitment to a luminal fate versus a basal fate is influenced by the expression of p63 and Notch 1 and Notch 3, respectively (Bouras et al., 2008; Raouf et al., 2008; Yalcin-Ozuysal et al., 2010) . Elf5 has emerged as a key in specifying luminal fate (Chakrabarti et al., 2012; Oakes et al., 2008) , while GATA3 directs differentiation to luminal epithelial cells (Asselin-Labat et al., 2007) . Our data presented herein reveal a critical role for Fbxo30-EG5 interaction mammary gland morphogenesis and, thus, suggest a critical checkpoint in mammopoiesis.
RESULTS

Mice with Targeted Mutations of Fbxo30 Reveal a Critical Role for Fbxo30 in Mouse Mammopoiesis
With the exception of a small stretch of 68 amino acids (aa) encoded by exon 3, the majority of the 746 aa of Fbxo30 are encoded by exon 2. We replaced the 3.5 kb genomic DNA encompassing the entire region of exon 2 (2.1 kb) and part of intron 2 (1.4 kb) with an in-frame GFP cDNA followed by a Neomycin cassette for selection ( Figure S1 ). The heterozygous mutant embryonic stem cells (ESCs) of C57BL/6 origin were used to generate chimeric mice. The null allele was germline-transmitted at a Mendelian ratio, suggesting that the +/+ females were 0%-12%, 55%-69%, and 82%-84%, respectively (Table S1 ). Only a small number of offspring were successfully nurtured by Fbxo30 À/À mice, usually after multiple pregnancies. Since the offspring of Fbxo30 À/À females developed normally with foster mothers and since necropsy revealed that the pups died of starvation (data not shown), we examined the mammary glands by histology and flow cytometry. In mammary gland whole mounts, virgin Fbxo30 À/À mice had atrophic mammary glands, characterized by both reduced branching and atrophic large ducts (images in Figure 1A ). The ratio between lateral branches and large ducts was decreased by Fbxo30 deletion ( Figure 1A , right panel). Pregnancy of wild-type (WT) mice is associated with increased branching and formation of alveolar structures in the branches. However, the Fbxo30 À/À mammary glands showed diminished branching with the alveoli forming adjacent to the large ducts ( Figure 1B ). Histological analysis revealed that, while WT mammary glands had proliferated massively at day 2 postpartum, those in Fbxo3 À/À mice remained largely atrophic ( Figure 4C ). Furthermore, while most of the glandules in Fbxo30 +/+ mice were filled with milk droplets, very few glandules in the Fbxo30 À/À mice contained milk droplets. These findings explained why the Fbxo30 À/À female failed to nurture the offspring.
To identify the relative number of luminal epithelial versus myoepithelial cells, we stained mammary sections with antibodies specific for cytokeratin (CK) 8 (luminal epithelial cells) or CK5 (basal myoepithelial cells). A reduction in the ratio of CK8 + / CK5 + cells was observed in the Fbxo30 À/À mammary glands (Figure 1D ). The normal development of myoepithelial cells was confirmed by using a panel of different markers, including CK14, CK17, and aSMA ( Figure 1E ). Remarkably, production of mucin by the luminal epithelial cells was largely abrogated by Fbxo30 deletion ( Figure 1E ).
We analyzed the cellular composition of the mammary glands using CD29, CD49f, CD61, and CD24 markers (Visvader, 2009 ). CD45 and CD31 were used to mark hematopoietic cells and vascular endothelial cells, respectively, for exclusion. We used flow cytometry to characterize the frequency of major cell types in the mammary gland. Representative fluorescence-activated cell sorting (FACS) profiles are shown in Figure 2A , while summary data of the major mammary gland cell types are shown in Figures 2B and 2C . Among the CD45 À
CD31
À cells, we observed a reduction in the proportion of CD24 + CD29 lo cells (Figure 2A , upper panels). Since essentially all of the CD24 + CD29 lo cells expressed high levels of CD49f (Figure 2A , lower panels), they belonged to luminal epithelial cells. Conversely, the percentage of CD24 + CD29 hi CD49 + myoepithelial cells was increased (Figure 2A) . In combination, the increase of myoepithelial and decrease of luminal epithelial cells resulted in a nearly 2-fold decrease in the relative abundance of luminal lineages (Figure 2B) . Correspondingly, the absolute numbers of luminal epithelial cells recovered from the Fbxo30 À/À was more severely reduced ( Figure 2C ). We used the accepted CD31 Figure 3A (left panels). However, the CD49f Figure 3B ). Despite their normal numbers, the size of the Fbxo30 À/À mammosphere was markedly reduced ( Figures 3C and 3D ). Taken together, the data in Figures 1, 2 , and 3 reveal that, while Fbxo30 is not required for mammary stem cell maintenance, it is required for differentiation and/or expansion of luminal progenitors into ductal and/or alveolar cells.
Fbxo30 Is the E3 Ligase of EG5
Fbxo30 is an orphan FBX with no known substrate. To fill in this gap, we isolated the FLAG-tagged Fbxo30-associated proteins by coimmunoprecipitation (coIP) with anti-FLAG antibodies. The proteins eluted with free FLAG peptides were digested with trypsin and analyzed by mass spectrometry. In addition to those from Fbxo30, peptides from Skp1 and Cullin were prominently represented, as expected. Interestingly, to our knowledge, seven unique peptides from the bipolar kinesin motor protein EG5 were identified ( Figure 4A ). To confirm this interaction, we probed anti-FLAG immunoprecipitates of either vector or Fbxo30-FLAG-transfected 293T cells. As shown in Figure 4B , anti-FLAG specifically co-precipitated EG5, Skp1, and Cul1. Since there are no commercial antibodies that satisfactorily immunoprecipitate FBXO30, we knocked in a 33 FLAG tag immediately before the stop codon in the FBXO30 open reading frame (Zhang et al., 2008) (Figure S2 ), and we used an anti-FLAG mAb to determine whether endogenous FBXO30 associates with EG5. As shown in Figure 4C (left panel), anti-FLAG precipitated FBXO30 and EG5 as well as polyubiquitinated proteins. Reciprocally, anti-EG5 specifically co-precipitated FBXO30 ( Figure 4C , right panel). These results confirmed the endogenous association between EG5 and FBXO30. Moreover, inhibition of proteasome increased EG5 in whole-cell lysate ( Figure 4D ). Using truncation mutant of Eg5, we observed that Fbxo30 interacts with the C-terminal region rather than the N-terminal and central parts of Eg5. The binding sites likely reside between aa 812 and 1,052 ( Figure 4E ).
To confirm that Fbxo30 is the E3 ligase for EG5, we isolated the Fbxo30 proteins from Fbxo30-FLAG transfectants and incubated them with Myc-tagged EG5 in the ubiquitinylation reaction mixture containing an E1 ubiquitin-activating enzyme and an E2 ubiquitin-conjugating enzyme. The extent of Eg5 ubiquitinylation was determined by immunoblot with an anti-polyubiquitin antibody. As shown in Figure 4F (upper panel), incubation of EG5 with Fbxo30 in the presence of E1 and E2 resulted in robust EG5 ubiquitinylation. After normalizing the amount of input protein, it was clear that EG5 ubiquitinylation did not require phosphorylation at either T927 or S1040, two phosphorylation sites critical for the regulation of EG5 activity by CDK1 and Plk1-NEK9-NEK6/7, respectively (Bertran et al., 2011; Blangy et al., 1995; Rapley et al., 2008) , as the relative amounts of polyubiquitinated EG5 increased even though the amounts of EG5 were reduced. The mechanism of reduced accumulation of mutant EG5 remains to be explained. To identify potential ubiquitylation sites, we focused on a patch of Lysine (K) between aa 891 and 913. As shown in Figure 4F (lower panel) , while mutations of K891R and K899R substantially reduced polyubiqutylation of Eg5, other mutations had minimal effect. These data further support ubiquitylation of Eg5 by Fbxo30, although they do not necessarily rule out additional ubiquitylation sites on Eg5.
Eg5 activities are tightly regulated during the cell cycle by phosphorylation (Bertran et al., 2011; Blangy et al., 1995; Rapley et al., 2008) . Since it is unclear whether Eg5 oscillates during cell cycle, we arrested, at G0/1, S, and M phases, the HCT116 cells expressing a FLAG-tagged FBXO30 under the control of its endogenous promoter. As shown in Figure 5A , EG5 levels increased progressively from G0/1 phase, to S phase, to M phase but reduced after the cells were released from the M phase arrest. The peak EG5 level at M phase correlated with the lowest FBXO30 level. To test whether Fbxo30 is responsible for Eg5 accumulation, we arrested WT and Fbxo30 À/À mouse embryonic fibroblasts (MEFs) at G1/G0, S, and M phases and compared the Eg5 levels. As shown in Figure 5B , Eg5 levels increased from G1 phase to S phase but peaked at the M phase in the WT MEF. Targeted mutation of Fbxo30 accelerated the increase of Eg5, as it peaked at S phase rather than M phase. Since Fbxo30 was expressed at lower levels at M phase, it was expected that deletion of this gene would not significantly affect EG5 levels ( Figure 5B ). The mechanism for fluctuations of Fbxo30 during cell cycles is currently unknown.
To determine whether Fbxo30 regulates Eg5 in mammary gland epithelial (MGE) cells, we arrested WT and Fbxo30 À/À MGE cells at S phase, and we determined Eg5 accumulation using immunofluorescence in conjunction with DAPI ( Figure 5C ). S-phase-synchronized Fbxo30 À/À MGE cells exhibited markedly increased overall Eg5 levels, as reflected by huge increases of Eg5 + spots. Despite comparable mRNA levels of the Kif11 gene, which encodes EG5 ( Figure 5D ), freshly isolated MGE cells had substantially elevated Eg5 protein, as revealed by western blot ( Figure 5E ). To determine whether Fbxo30 regulates Eg5 in vivo, we compared the cellular levels of Eg5 in mammary glands from WT and Fbxo30 À/À mice by immunofluorescence. This analysis revealed a marked increase in the cellular concentration of EG5 in Fbxo30 À/À mammary gland ( Figure 5F ).
As an ATPase motor protein, Eg5 is targeted to the mitotic spindle and centrosome and plays a critical role in mitosis (Mardin and Schiebel, 2012; Nigg and Stearns, 2011) . Consistent with the abnormal levels of Eg5 in Fbxo30 À/À MGE cells (Figure 5 ), the proliferation rate of Fbxo30 À/À MGE cells also was markedly reduced over three passages ( Figure 6A ). To determine whether the defective proliferation in MGE cells is attributable to increased Eg5 activity, we used small hairpin RNA (shRNA) to silence the Kif11 gene in the Fbxo30 À/À MGE cells ( Figure 6B , right panel). Consistent with a critical role for Eg5 in cell proliferation (Bertran et al., 2011; Blangy et al., 1995; Rapley et al., 2008) , growth of WT MGE cells was inhibited by shRNA specific for the Kif11 gene. In contrast, shRNA silencing of Kif11 increased the proliferation of Fbxo30 À/À MGE cells (Figure 6B) . Furthermore, Kif11 shRNA significantly increased the size of mammospheres ( Figure 6C ). Reintroduction of WT Fbxo30 to the mammary epithelial cells through ectopic expression partially restored the mammosphere formation ( Figure 6D ). While these data confirmed the function of Fbxo30, they also suggested that ectopic expression of Fbxo30 does not fully recapitulate the function of endogenous alleles.
To determine whether increased EG5 is responsible for the defective mammopoiesis during pregnancy, we treated day 6 pregnant Fbxo30 À/À mice with the Eg5 inhibitor monastrol (Mayer et al., 1999) , and we analyzed the mammary gland morphology at day 12. As shown in Figures 6E and 6F , a shortterm treatment of the Fbxo30 À/À mice with monastrol substantially rescued mammopoiesis, as revealed by the increased branching and distance between the alveoli and the large ducts. Therefore, elevated Eg5 activity is responsible for the defective mammopoiesis of Fbxo30 À/À MGE cells in both virgin and pregnant mice.
Given the role of Eg5 in centrosome separation (Mardin et al., 2011; Mardin and Schiebel, 2012) , we evaluated the impact of Fbxo30 mutation on mitosis. Based on DNA content, it was clear that deletion of Fbxo30 caused G2/M arrest and polyploidy ( Figure 7A ). To understand how Fbxo30 defects affect genome instability and G2/M arrest, we analyzed Eg5 distribution and mitotic spindles in mitotic WT MGE cells. We found that Eg5 was targeted to bipolar mitotic spindles, with a higher concentration at the two poles of the MGE cells. However, in the Fbxo30 À/À MGE cells, Eg5 was targeted to multipolar spindles or bipolar multiple spindles, resulting in abnormal separation of chromosomes ( Figures 7B and 7C ). This was due to overactive Eg5, as the number of cells with abnormal spindles was normalized by Eg5 inhibitor ( Figure 7D ). Consistent with increased multipolar spindles, targeted mutation caused centrosome amplification, as indicated by the percentage of MGE cells with more than two centrosomes ( Figure 7E ). This was mediated by increased Eg5, as the reduction of Eg5 through shRNA silencing of Kif11 attenuated the defects ( Figure 7F (B) Confirmation of EG5-SCF complex by coIP. cDNA encoding FLAG-tagged Fbxo30 was transfected into 293T cells. After immunoprecipitation with anti-FLAG, the precipitates were probed for EG5, SKP1, and CUL1 by their specific antibodies. (C) Association between endogenous EG5 and Fbxo30. The endogenous FBXO30 was tagged with a 33 FLAG epitope by homologous knockin (see Figure S2 ). The left panel shows that anti-FLAG-Fbxo30 co-precipitated endogenous EG5; the right panel shows co-precipitation of endogenous FBXO30 by anti-EG5.
(D) Impact of proteasome inhibitor MG132 and M phase arrest on endogenous EG5 levels: effect of ectopically expressed Fbxo30. After 24 hr of being transfected with empty vector or Fbxo30-FLAG-expressing vector, the 293T cells were treated with 2.5 mM MG132 or 50 nM nocodazole for an additional 6 hr before being lysed for western blot. Note that, in vector control, EG5 levels increased after MG132 treatment and that EG5 overexpression decreased EG5 at M phase. Previous studies have demonstrated that EG5 targeting to the spindle pole is regulated by phosphorylation at sites T927 and S1040 by Cdk1 and Plk1-Ned6, respectively (Bertran et al., 2011; Blangy et al., 1995; Rapley et al., 2008) , and their phosphorylation is critical for correct formation of mitotic spindle. Our data demonstrate that phosphorylation of neither site is required for EG5 ubiquitinylation. Thus, Eg5 is subject to at least two layers of regulation: Cdk1-and Plk1-Nek9-Nek6/7-mediated phosphorylation, which regulates localization but not Eg5 levels, and the Fbxo30-mediated ubiquitinylation, which controls Eg5 levels. A phospho-peptide analysis revealed that endogenous Eg5 was phosphorylated only at the T927 and S1040 sites in vivo (Rapley et al., 2008) , and since mutation of neither site abolished Eg5 ubiquitinylation, it is likely that Fbxo30-mediated Eg5 degradation occurs either by a phosphorylation-independent pathway, which would be similar to the Fbxo1-CP110 and Fbx011-BCL6 interactions (D'Angiolella et al., 2010; Duan et al., 2012) , or by phosphorylation at other sites. Two recent studies demonstrated that the APC/C-CDH1 complex also caused ubiquitinylation of EG5 (Drosopoulos et al., 2014; Eguren et al., 2014) . Given the specific activation of the APC/C-CDH1 during mitosis, and given the relatively low expression and small effect of Fbxo30 deficiency on EG5 levels at M phase, we suggest that Fbxo30 and APC/C-CDH1 may function at different phases of the cell cycle in regulating EG5 levels, although the possibility that the different E3 may function in different cell types cannot be ruled out. The mitotic spindle defects observed in the Fbxo30 À/À mammary epithelial cells is a direct consequence of Eg5 overexpression, as it can be normalized by shRNA silencing of EG5. Moreover, since normalization of Eg5 activity by monastrol and/or Kif11 shRNA rescued defects in centrosome homeostasis, cellular proliferation, mammosphere formation, and mammopoiesis, the defective regulation of EG5 levels is likely the root cause of genome instability and defective mammopoiesis in the Fbxo30 À/À mice.
Apart from a critical function of Fbxo30 in mammopoiesis described herein, a recent report suggested that Fbxo30 was negatively regulated by the BMP-signaling pathway and contributed to loss of muscle mass caused by defective BMP signaling (Sartori et al., 2013) . However, the Fbxo30 substrate involved in the regulation of muscle mass was not identified. Paradoxically, mice lacking Fbxo30 have normal development, fertility, and lifespan. Since the developmental pathway for mammary gland is similar to that of T cell differentiation (Watson and Khaled, 2008) , we investigated the possible role of EG5 in the development and accumulation of T cells in the thymus and spleen. We found that cellular compositions of spleen and thymus were largely unaffected by Fbxo30 deletion (Figures S4 and S5) . As a potential explanation for lack of function of Fbxo30 in spleen cells, we found that expression of Fbxo30 among spleen cells was considerably lower than in the mammary epithelial cells ( Figure S6A ). Correspondingly, the levels of EG5 were largely unaffected by deletion of the Fbxo30 gene ( Figure S6B ). With recent identification of APC/ C-CDH1 as an E3 ligase for EG5 (Drosopoulos et al., 2014; Eguren et al., 2014) , it is possible that this or another E3 may serve to regulate EG5 depending on the cell types studied.
Accumulating data have demonstrated that some of the most critical regulators of centrosome homeostasis, including Plk4, SAS6, and Cp110, are regulated by SCF-type E3 ligase (Silverman et al., 2012) . Our data demonstrate that Eg5 abundance, as well as its oscillation during cell cycle, also is regulated by an E3 ligase. It is of note that Eg5 levels frequently are elevated in human cancer and that such elevation correlates with poor prognosis (Ding et al., 2011; Saijo et al., 2006) . Since transgenic expression of Eg5 leads to abnormal centrosome homeostasis, genetic instability, and cancer development (Castillo et al., 2007) , it would be of interest to test whether Fbxo30 defects may contribute to Eg5 elevation in human cancer.
EXPERIMENTAL PROCEDURES
Generation of Fbxo30
À/À Mice The mice were generated by inGenious Targeting Laboratories through a research contract. The constructs generated are diagrammed in Figure S1 . Briefly, a 13.2-kb region used to construct the targeting vector was first subcloned from a positively identified B6 BAC clone using a homologous recombination-based technique. The region was designed such that the short homology arm (SA) extended 1.9 kb to the 5 0 Neo cassette. The long homology arm (LA) started at the 5 0 end of the GFP cassette and was 7.8 kb. The GFP/Neo cassette was inserted 3 bp before the ATG of exon 1 and replaced $3.5 kb of the gene sequence. The targeting vector was confirmed by restriction analysis after each modification step and by sequencing using primers designed to read from the LacZ/Neo cassette into the 5 0 end of the SA (N1) and the 3 0 end of the LA (GFP1) or from primers that anneal to the vector sequence, P6 and T7, and read into the 5 0 and 3 0 ends of the BAC subclone. The BAC was subcloned into a $2.4-kb backbone vector containing an ampicillin selection cassette for retransformation of the construct prior to electroporation. The total size of the targeting construct (including vector backbone and GFP/Neo cassette) was 14.7 kb. The targeting vector (10 mg) was linearized by AscI and then transfected by electroporation of iTL C57 BL/6 ESCs. After selection in G418, surviving clones were expanded for PCR analysis to identify recombinant ESC clones. Primers, A1 was designed downstream (3 0 ) to the SA outside the region used to generate the targeting construct. ESCs with a targeted locus were injected into albino C57BL/6 blastocysts to generate chimeric mice. Chimera were identified by coat color and used to generate mice with germline transmission of the targeted Fbxo30 À/À locus.
Generation of HCT116 Cell Line with FLAG-Tagged Endogenous Fbxo30
The vector construction and knockin by homologous recombination were based on a previous report (Zhang et al., 2008) . Briefly, the targeting vector was constructed by PCR using genomic DNA as the template for the homologous left arm. Homologous recombination was screened by PCR with primers derived from the neomycin resistance gene and the upstream region of the left homologous arm. Two clones were identified from two 96-well plates of G418-resistant clones. The neomycin resistance gene was excised by Cre recombinase. The following primers were used: 3FLAG KI FBXO30 left arm F, GGGAAAG/ideoxyU/atttgtaaagatgaggggcttg; 3FLAG KI FBXO30 left arm R, GGAGACA/ideoxyU/GcAAGTACAGGTTTTAAAACTGAGCG; 3FLAG KI FBXO30 right arm F, GGTCCCA/ideoxyU/AAGTTGTAATATTACTAGCACATA; 3FLAG KI FBXO30 right arm R, GGCATAG/ideoxyU/ ACTTTCTTGGTGG TGAAGCCTA; 3FLAG KI FBXO30 left screening F; tctaggtctgtcctgctctgc; 3FLAG KI FBXO30 right screening R, tttttaagcagaccacatcagg; 3FLAG KI FBXO30 cre F, GAAGGACGTTCACTACGCTCA; and 3FLAG KI FBXO30 Cre R, TTCCAAAAATTTCACACATTTCA.
Immunofluorescence
After deparaffinization and rehydration of slides with Xylene and ethanol, the mammary gland sections from Fbxo30 knockout and WT mice were treated with 10 mM sodium citrate buffer (pH 6.0). The sections were permeabilized with 0.3% Triton X-100 in 10 mM Tris-HCl buffer for 30 min. After blocking with 2% BSA for 60 min, sections were incubated with primary antibody diluted in 10 mM Tris-HCl buffer containing 2% BSA at 4 C overnight, with subsequent staining with secondary antibody in BSA-Tris-HCl buffer at room temperature for 2-4 hr. The nuclei were stained with DAPI. Slides were mounted with Prolong Antifade mounting buffer (Invitrogen). Antibodies for EG5 (NB500-181, Novus), b-tubulin (F2043, Sigma), g-tubulin (T5326, Sigma), Keratin 5 (AF138, Covance), Keratin 8 (TROMA-I, Developmental Studies Hybridoma Bank [DSHB]), Keratin K14 (ab7800, Abcam), Keratin K17 (ab53707, Abcam), and aSMA (ab5694, Abcam) were used for immunofluorescence.
Transplantation
Female mice (3 weeks old) were anesthetized with Ketamine and Xylazine. An inverted Y incision was made from the midline point between the fourth set of nipples and ending at a point between the fourth and fifth sets. The fourth and fifth fat pads on each side were exposed using forceps to separate the skin from the body cavity. Half of the fourth mammary fad pad from the fourth nipple to the lymph node was removed using scissors to clear the mammary epithelium, and 1 3 10 6 mammary epithelial cells suspended in 30 ml Hank's balanced salt solution plus 2% fetal bovine serum (FBS) were injected into the mammary epithelium-cleared fat pads. After cell transplantation, the incision was sutured with 9-mm autoclips, and the mice were placed in a clean cage and were monitored for a short period of time. Staples were removed 2 weeks after surgery.
Isolation and Culture of Mammary Gland Epithelia
Mammary glands were minced with razor blades on a sterile surface and then transferred to a tube containing dissociation solution (EpiCult-B medium with collagenase and Hyaluronidase, STEMCELL Technologies) and incubated for 7 hr at 37 C with occasional pipetting and vortexing. After dissociation, the cells were collected by centrifugation at 350 3 g. Pre-warmed Trypsin-EDTA (1-5 ml) was added to the partially dissociated tissue and mixed by pipetting for 1 to 3 min. Cold Hank's balanced salt solution (10 ml) supplemented with 2% FBS was added to stop the digestion, and the cells were again collected by centrifugation at 350 3 g for 5 min. To dissociate the clumps, 2 ml pre-warmed 5 mg/ml Dispase (07913, STEMCELL Technologies) and 200 ml 1 mg/ml DNase I (07900, STEMCELL Technologies) were added to the pellet and then pipetted for 1 min with a P1000 micropipetor to further dissociate cell clumps. The cell suspension was then diluted with an additional 10 ml cold Hank's balanced salt solution supplemented with 2% FBS and filtered through a 40-mm cell strainer into a new 50-ml centrifuge tube. Cells were collected after centrifugation and red blood cells were lysed as needed.
Flow Cytometry
The isolated cells from the mammary glands of WT and Fbxo30 À/À mice were stained with fluorochrome-conjugated anti-CD31, CD45.2, CD61, CD24, CD49f, CD29, Sca-1, and CD133 monoclonal antibodies (eBioscience). The stained cells were analyzed by a fluorescence-activated cell analyzer (LSR II).
Mammosphere Assay
The isolated cells from the mammary glands of either WT or Fbxo30 À/À mice were suspended in the EpiCult-B (STEMCELL Technologies) and seeded in ultra-low attachment six-well plates (Corning). The cells were cultured for 7 days and the formed mammospheres were photographed. The surface areas of the mammospheres were measured based on analysis of the images using Scion image software.
Whole-Mount Staining
Whole-mount preparations of mammary glands were performed according to the protocol reported by Mueller et al. (2002) . Briefly, inguinal number 4 mammary glands were dissected, spread on glass slides, and fixed overnight in Carnoy's fixative. The next day, the tissues were hydrated and then stained in carmine-aluminum stain overnight. The tissues were dehydrated, cleared in xylene, and mounted between two glass slides using Permount mounting media.
shRNA Silencing
The lentiviral vector pLenti6/V5-TOPO, obtained from Invitrogen, was modified by replacing the CMV promoter with a U6 promoter to drive an shRNA-expressing cassette and inserting a pGK-driven EGFP cassette and a blasticidin-resistant cassette. The sequence used to silence Kif11 was 5 0 -TGCAGGT CAGATTTACACT-3 0 (sh1) and TATTGTCTTCAGGTCTTCA (sh2). The MGE cell cultures were infected with either scrambled shRNA control lentivirus or lentivirus encoding Kif11-shRNA for 24 hr. After recovery for an additional 48 hr, the cultures were used for assays.
In Vitro Ubiquitinylation Assay All the reagents used for the in vitro ubiquitinylation assay were purchased from Boston Biochem (K930). Ubiquitinylation was performed according to standard protocols provided by the supplier, with modifications. In brief, HEK293 cells were transfected with Eg5-Myc or its phosphorylation site mutants. Anti-Myc immunoprecipitate beads were mixed with components of the ubiquitinylation system in the presence or absence of Fbxo30 proteins, which were eluted using FLAG peptide from anti-FLAG immunoprecipitates of transfected HEK293 cells using FLAG peptide. After 2 hr of incubation at 37 C, the beads were washed with a 1% Triton X-100 Tris-HCl buffer, resuspended with a 2% SDS Tris-HCl buffer, and re-immunoprecipitated with an anti-Myc antibody after a 10-fold dilution with a 1% Triton X-100 Tris-HCl buffer. The final immunoprecipitates were resuspended in SDS loading buffer, heated for 3 min at 90 C, and resolved by 10% SDS-PAGE.
Immunoprecipitation and Western Blot
Cells or tissues were lysed with a 1% Triton X-100 buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 40 mM NaF, 2 mM DTT, and a protease and phosphatase inhibitor cocktail (Sigma). The cleared lysates were immunoprecipitated with protein G beads and antibody at 4 C with overnight shaking.
After washing with the lysis buffer for three times, the beads were treated with SDS loading buffer and the eluted proteins were analyzed by western blot. The EG5 antibodies used for western blot and immunoprecipitation were a rabbit antibody (ab61199, Abcam) and a mouse antibody (NB100-78467, Novus Biologicals), respectively.
Measurement of Duct and Branch Lengths
The ratio of branch over duct length was measured using a method developed for measuring neurite and axon lengths (Kim et al., 2013; Sterne et al., 2015) . The Neurolucida software (MBF Bioscience) was used to trace and measure the length of duct and that of the branches in a double-blind fashion. Total lengths of either ducts or branches in all areas captured in low-power images (see Figures 1A, 1B , and 6D as examples) were integrated to calculate the branch over duct ratios.
Statistics
Student's t test was used to determine statistical significance between two groups of samples. 
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